IQV

IQVIA HOLDINGS INC.

Ticker: IQVIndustrialsProfessional ServicesS&P 500
HQ DURHAM, NCCIK 1478242FY end 12-31Book / share $36.60Shares 169M
Revenue (FY)
$16.31B+5.87%
TTM $16.98B
Op. margin
13.38%-0.92%
TTM 12.95%
Net income
$1.36B-0.87%
TTM $1.38B
Operating cash
$2.65B-2.28%
TTM $2.82B
Free cash flow
$2.05B-2.98%
TTM $2.18B
Return on equity
22.27%-1.27%
TTM 22.28%
Debt / equity
2.42+0.11%
TTM 2.59
Shares outstanding
173.5M-5.40%
TTM 168.6M

The business

IQVIA Holdings Inc. (NYSE: IQV) is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. The company operates at www.iqvia.com and serves as a critical partner throughout the pharmaceutical development and commercialization lifecycle.

IQVIA maintains one of the largest and most comprehensive collections of healthcare information globally, encompassing more than 1.2 billion comprehensive, longitudinal, unique non-identified patient records. The company's proprietary data set spans approximately 68 petabytes of information sourced from approximately 150,000 data suppliers and covering over one million data feeds worldwide. This information foundation enables IQVIA to deliver insights on approximately 90 percent of the world's pharmaceuticals by sales volume.

The company operates through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Effective January 1, 2026, the company reorganized into Commercial Solutions and Research & Development Solutions segments. Technology & Analytics Solutions provides cloud-based SaaS applications, real-world evidence platforms, analytics and consulting services, and information offerings across more than 100 countries. Research & Development Solutions delivers clinical trial support, laboratory services, patient recruitment, and strategic planning capabilities. Contract Sales & Medical Solutions offers healthcare provider engagement, patient engagement programs, and medical services to support product commercialization.

IQVIA employs approximately 89,000 people across more than 100 countries, including over 31,000 Technology & Analytics Solutions employees, approximately 51,000 Research & Development Solutions employees, and approximately 7,000 Contract Sales & Medical Solutions employees. The company serves a diversified client base exceeding 10,000 customers, with nearly all of the top 100 global pharmaceutical and biotechnology companies as clients. No single client represents more than 10 percent of total revenues.

The company addresses a market opportunity estimated at approximately $335 billion, consisting of outsourced research and development, real-world evidence and connected health, and technology-enabled clinical and commercial operations markets. IQVIA's competitive advantages include its proprietary healthcare data infrastructure, advanced analytics capabilities, global presence, domain expertise, and integrated service offerings that enable clients to reduce development timelines and improve operational efficiency.

Sector
Industrials
Industry
Professional Services
HQ
DURHAM, NC
FY end
12-31
CIK
1478242
SIC
8731
Financial performance · annual
20132025
$-1.70B$3.40B$8.49B$13.59B$18.68B2013201420152016201720182019202020212022202320242025TTMTTMTTM

Ownership

Who holds IQVIA HOLDINGS INC. — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30

779
funds hold it
2 of 35
superinvestors hold it
$11.53B
fund-held value
37.6%
of shares held by funds
8
bond issues held by funds

Top fund holders

Fund% of fundValue
VANGUARD TOTAL STOCK MARKET INDEX FUND
VTI · VANGUARD INDEX FUNDS
0.04%$1.02B
VANGUARD 500 INDEX FUND
VOO · VANGUARD INDEX FUNDS
0.05%$835.37M
VANGUARD MID-CAP INDEX FUND
VO · VANGUARD INDEX FUNDS
0.31%$698.77M
Oakmark Select Fund
OAKLX · HARRIS ASSOCIATES INVESTMENT TRUST
6.05%$503.43M
Oakmark Fund
OAKMX · HARRIS ASSOCIATES INVESTMENT TRUST
2.06%$495.67M

Superinvestors in IQVIA HOLDINGS INC.

Bill NygrenINCREASED
Harris Associates (Oakmark)
3.1%
Tom GaynerUNCHANGED
Markel Group (Markel-Gayner)
0.1%

Share of each manager's reported 13F portfolio.

Bonds held by funds

Funds report holding 8 issues of IQVIA HOLDINGS INC.'s debt, $2.31B at fund-held market value — what funds hold, not the company's debt outstanding. Weighted-average coupon 5.79%, maturing 20262033.

IssueCouponMaturesFundsFund-held
IQVIA INC 144A LIFE SR UNSEC 6.25% 06-01-326.250%2032-06-01260$789.35M
IQVIA Inc5.000%2026-10-1575$400.74M
IQVIA Inc5.000%2027-05-15114$367.35M
IQVIA INC6.250%2029-02-01116$283.45M
IQVIA Inc5.700%2028-05-1585$257.99M
IQVIA INC6.500%2030-05-1596$211.00M
IQVIA INC4.625%2033-06-152$4.01M
IQV 5.7 05/15/28 144A5.700%2028-05-151$0.07M

Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.

Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.

Go deeper in your own AI

15 years of statements, narrative and filings — queryable over MCP.

Read IQV's last four 10-Qs: what changed in segment trends, margins and management's narrative?
Run in your AI →

Professionals can also use the built-in AI chat (subscription + your own Anthropic key).

15 years of IQVIA HOLDINGS INC.'s financials

Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.

Sign in free